SRPT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

379.47M

-42.37%

-1.384

-192.26%

375.70M

-49.56%

0.314

-106.82%

379.61M

-37.88%

0.545

-71.19%

Estimates Revision

The market is revising No Change the revenue expectations for Sarepta Therapeutics, Inc. (SRPT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 7.78%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+7.78%

In Past 3 Month

21 Analyst Rating

Wall Street analysts forecast SRPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRPT is 18.35 USD with a low forecast of 5.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

12 Hold

5 Sell

Hold

Current: 0.000

Low

5.00

Averages

18.35

High

37.00

Current: 0.000

Low

5.00

Averages

18.35

High

37.00

Citizens

Outperform

maintain

$87 -> $120

2025-12-12

Reason

Citizens

Price Target

$87 -> $120

2025-12-12

maintain

Outperform

Reason

Citizens raised the firm's price target on Structure Therapeutics to $120 from $87 and keeps an Outperform rating on the shares. The Phase 2b data for aleniglipron fundamentally derisk the small molecule GLP agonist, and the firm is not losing the forest through the trees, the analyst tells investors in a research note. There could be ongoing debate on aleniglipron's tolerability, but there is solid evidence to support an improved Phase 3 profile, the firm adds.

Wedbush

NULL -> Outperform

initiated

$32

2025-12-09

Reason

Wedbush

Price Target

$32

2025-12-09

initiated

NULL -> Outperform

Reason

Wedbush initiated coverage of Sarepta with an Outperform rating and $32 price target.

Wedbush

Outperform

initiated

$32

2025-12-09

Reason

Wedbush

Price Target

$32

2025-12-09

initiated

Outperform

Reason

As previously reported, Wedbush initiated coverage of Sarepta with an Outperform rating and $32 price target. The firm sees the early summer selloff due to Elevidys patient deaths as overdone, and even after the subsequent recovery following the Food and Drug Administration's quick reversal for Elevidys to remain available to ambulatory patients, Wedbush sees further upside from potential re-approval in non-ambulatory patients as well. On exon-skipping products that have stably generated close to $1B in annual sales, despite the recent negative ESSENCE study data and emerging competition, the firm projects continued patient uptake based on a high compliance rate that Sarepta has reported, comprehensive real world data supporting clinical benefit, and favorable key opinion leader feedback.

Bernstein

Market Perform

maintain

$18 -> $20

2025-11-25

Reason

Bernstein

Price Target

$18 -> $20

2025-11-25

maintain

Market Perform

Reason

Bernstein raised the firm's price target on Sarepta to $20 from $18 and keeps a Market Perform rating on the shares. The firm cites higher estimates for Elevidys, partially offset by a slightly lower multiple reflecting greater uncertainty on PMO durability post-ESSENCE.

Wells Fargo

Overweight

downgrade

$18 -> $16

2025-11-11

Reason

Wells Fargo

Price Target

$18 -> $16

2025-11-11

downgrade

Overweight

Reason

Wells Fargo lowered the firm's price target on Wave Life Sciences (WVE) to $16 from $18 and keeps an Overweight rating on the shares. The firm is positive on the INHBE/Activin E MoA in obesity. That said, Wells thinks 6 months data may be more informative. Sarepta (SRPT) DMD update adds risk, but the firm believes 'N531 is approvable.

Mizuho

Neutral -> Outperform

upgrade

$19 -> $26

2025-11-05

Reason

Mizuho

Price Target

$19 -> $26

2025-11-05

upgrade

Neutral -> Outperform

Reason

Mizuho upgraded Sarepta to Outperform from Neutral with a price target of $26, up from $19. The firm has greater confidence in the adoption of Elevidys following the company's Q3 report. Strong demand drove outperformance in Q3 despite the commercial pause and heightened safety concerns, the analyst tells investors in a research note. Mizuho says Sarepta's commentary points to continued favorable coverage. It sees a favorable risk/reward at current share levels.

Valuation Metrics

The current forward P/E ratio for Sarepta Therapeutics Inc (SRPT.O) is 89.24, compared to its 5-year average forward P/E of 5.74. For a more detailed relative valuation and DCF analysis to assess Sarepta Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

5.74

Current PE

89.24

Overvalued PE

43.08

Undervalued PE

-31.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

3.61

Current EV/EBITDA

27.78

Overvalued EV/EBITDA

88.93

Undervalued EV/EBITDA

-81.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.47

Current PS

1.46

Overvalued PS

9.35

Undervalued PS

3.59

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 12693.27% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SRPT News & Events

Events Timeline

No data

News

9.0

01-07Businesswire

Sarepta Submits Clinical Trial Application for Huntington's Disease Therapy, Anticipates 2026 Start

1.0

01-05Businesswire

Sarepta to Present at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

5.0

2025-12-31Newsfilter

Sarepta Grants 55,118 RSUs to 10 Employees Under 2024 Incentive Plan

People Also Watch

Frequently Asked Questions

What is Sarepta Therapeutics Inc (SRPT) stock price today?

The current price of SRPT is 23.83 USD — it has increased 2.94 % in the last trading day.

What is Sarepta Therapeutics Inc (SRPT)'s business?

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

What is the price predicton of SRPT Stock?

What is Sarepta Therapeutics Inc (SRPT)'s revenue for the last quarter?

Sarepta Therapeutics Inc revenue for the last quarter amounts to 399.36M USD, decreased -14.52 % YoY.

What is Sarepta Therapeutics Inc (SRPT)'s earnings per share (EPS) for the last quarter?

Sarepta Therapeutics Inc. EPS for the last quarter amounts to -1.80 USD, decreased -629.41 % YoY.

What changes have occurred in the market's expectations for Sarepta Therapeutics Inc (SRPT)'s fundamentals?

How many employees does Sarepta Therapeutics Inc (SRPT). have?

Sarepta Therapeutics Inc (SRPT) has 1372 emplpoyees as of January 10 2026.

What is Sarepta Therapeutics Inc (SRPT) market cap?

Today SRPT has the market capitalization of 2.50B USD.